Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Pfizer may have poked the bear.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
Patient investors can profit from small-cap biotech stocks that often slide once positive news comes out.